Russia's sovereign wealth fund and its partner Chemrar will supply the COVID19 drug Avifavir to 17 additional countries, the fund said in a statement on Thursday.
MOSCOW: Russia’s sovereign wealth fund and its partner Chemrar will supply the COVID-19 drug Avifavir to 17 additional countries, the fund said in a statement on Thursday.
Avifavir gained approval from the Russian health ministry in May and is based on favipiravir, which was developed in Japan and is widely used there as the basis for viral treatments.
Clinical trials in Japan and Russia have confirmed those drugs’ efficacy, the Russian Direct Investment Fund (RDIF) said in a statement.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor
Comments
0 comment